Human Research Limitations Human research specifically examining exogenous IGF-1 LR3 administration is remarkably limited in peer-reviewed scientific literature - searches of PubMed and other databases yield virtually no controlled clinical trials for any indication
Lawitz EJ, Fraessdorf M, Neff GW, Schattenberg JM, Noureddin M, Alkhouri N, Schmid B, Andrews CP, Takcs I, Hussain SA, Fenske WK, Gane EJ, Hosseini-Tabatabaei A, Sanyal AJ, Mazo DF, Younes R
doi: 10.1016/0304-4165(90)90147-O
Weight loss is rarely linear, and plateaus are common and normal during treatment
The lowest price of $149 per month for the lowest dose of the pill form of the drugs will be offered to consumers and Medicare and Medicaid when the drugs reach the market
*ENERGY